With around 10 new ADC commercial launches over the coming decade, the report says the overall market will be worth USD 10 billion annually by 2025 and with most ADC research currently only in pre-clinical stages, we are yet to see the full market potential that ADCs are to contribute to the treatment of cancer.

The pharmaceutical industry is making every effort to produce the best next generation of ADCs by pioneering new approaches to eliminate cancer stem cells.

As a result new innovations in conjugation methods and linker technology are bursting into the clinic at a rapid rate.

Benefits of attending

• Hear the latest approaches to improve the therapeutic window of your ADC
• Discuss the latest innovations in site-specific conjugation technology
• Participate in insightful discussions on; novel payloads, folic acid drug conjugates, linker technology and many more!
• Engage in our interactive sessions and speed networking to solidify your learning experience amongst your peers